Corindus to Present at Upcoming 2018 Healthcare Conferences
November 07 2018 - 3:30PM
Business Wire
Corindus Vascular Robotics, Inc. (NYSE American: CVRS), a
leading developer of precision vascular robotics, announced today
that management will present at two investor conferences in
November as follows:
Conference: Stifel 2018 Healthcare Conference Date:
Wednesday, November 14, 2018 Time: 12:30 p.m. Eastern Standard Time
Location: Lotte New York Palace Hotel, NYC Presenter: David Long,
Chief Financial Officer Webcast:
http://wsw.com/webcast/stifel14/cvrs/
Conference: Canaccord Genuity Medical Technologies
& Diagnostics Forum Date: Thursday, November 15, 2018 Time:
2:30 p.m. Eastern Standard Time Location: Westin Grand Central
Hotel, NYC Presenters: Mark Toland, President and Chief Executive
Officer and David Long, Chief Financial Officer Webcast:
http://wsw.com/webcast/canaccord32/cvrs/
The presentations will be webcast live at the aforementioned
time, and archived for 30 days thereafter, via the company’s
website at investors.corindus.com, under the News & Events
Section.
About Corindus Vascular Robotics
Corindus Vascular Robotics, Inc. is a global technology leader
in robotic-assisted vascular interventions. The Company's CorPath®
System is the first FDA-cleared medical device to bring robotic
precision to percutaneous coronary and vascular procedures. During
the procedure, the interventionalist sits at a radiation-shielded
workstation to advance guide catheters, stents, and guidewires with
millimeter-by-millimeter precision. The workstation allows the
physician greater control and the freedom from wearing heavy lead
protective equipment that causes musculoskeletal injuries. CorPath
GRX is the second generation robotic-assisted technology offering
enhancements to the platform by adding important key upgrades that
increase precision, improve workflow, and extend the capabilities
and range of procedures that can be performed robotically. With the
CorPath System, Corindus Vascular Robotics brings robotic precision
to interventional procedures to help optimize clinical outcomes and
minimize the costs associated with complications of improper stent
placement during manual procedures. For additional information,
visit www.corindus.com, and follow @CorindusInc.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20181107005866/en/
Trevi CommunicationsMedia Contacts:Lisa Murray, 978-750-0333
ext. 2lisa@trevicomm.comorIn-Site Communications, Inc.Investor
Contact:Lisa Wilson, 917-543-9932ir@corindus.com
Corindus Vascular Robotics (AMEX:CVRS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Corindus Vascular Robotics (AMEX:CVRS)
Historical Stock Chart
From Jul 2023 to Jul 2024